HPLC–MS/MS Analysis of a Traditional Chinese Medical Formulation of Bu-Yang-Huan-Wu-Tang and Its Pharmacokinetics after Oral Administration to Rats

Lee-Hsin Shaw1, Lie-Chwen Lin1,2, Tung-Hu Tsai1,3,4*

1 Institute of Traditional Medicine, National Yang-Ming University, Taipei, Taiwan, 2 National Research Institute of Chinese Medicine, Taipei, Taiwan, 3 Graduate Institute of Acupuncture Science, China Medical University, Taichung, Taiwan, 4 Department of Education and Research, Taipei City Hospital, Taipei, Taiwan

Abstract

Bu-yang-huan-wu-tang (BYHWT) is one of the most popular formulated traditional Chinese medicine prescriptions, and is widely used for the prevention and treatment of ischemic cardio-cerebral vascular diseases and stroke-induced disability. A specific high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) has been developed and validated for the simultaneous quantification of the nine main bioactive components, i.e., astragaloside I, astragaloside II, astragaloside IV, formononetin, ononin, calycosin, calycosin-7-O-β-d-glucoside, ligustilide and paeoniflorin in rat plasma after oral administration of BYHWT extract. This method was applied to investigate the pharmacokinetics in conscious and freely moving rats. No significant matrix effects were observed. The overall analytical procedure was rapid and reproducible, which makes it suitable for quantitative analysis of a large number of samples. Among them, three astragalosides and four isoflavones in A. membranaceus, ligustilide in Radix Angelicae Sinensis and Rhizoma Ligustici Chuanxiong and paeoniflorin in Radix Paeoniae Rubra were identified. This developed method was then successfully applied to pharmacokinetic studies of the nine bioactive constituents after oral administration of BYHWT extracts in rats. The pharmacokinetic data demonstrated that the isoflavone and ligustilide presented the phenomenon of double peaks. The other herbal ingredients of formononetin, ononin, calycosin, calycosin-7-O-β-d-glucoside and paeoniflorin appeared together in a single and plateau absorption phase. These phenomena suggest that these components may have multiple absorption sites, regulation of enterohepatic circulation or the gastric emptying rate, or there is ingredient-ingredient interaction. These pharmacokinetic results provide a constructive contribution to better understand the absorption mechanism of BYHWT and to support additional clinical evaluation.

Introduction

BYHWT is one of the most popular formulated traditional Chinese medicine (TCM) prescriptions, with wide use in clinical medication for the prevention and treatment of ischemic cardio-cerebral vascular diseases and stroke-induced disability. BYHWT was originally recorded in the traditional herbal text Yi-Lin-Gai-Cuo (Chinese mean: corrections of errors among physicians) from the Qing Dynasty, published in 1830. From the viewpoint of traditional Chinese medicine, it was used to invigorate the body, promote blood circulation, and activate energy (qi) flow through energy meridians. Considerable clinical evidence has indicated that the ameliorative effects of BYHWT on coronary heart disease with qi deficiency and blood stasis syndrome in rats are associated with the inhibition of C-reactive protein and the CD40 gene, as well as the regulation of endothelium-derived vasoactive factors [1]; and mediating by the improvement of hemorheological disorders and energy metabolism [2]. A previous study has found that BYHWT could protect mice against ischemic stroke and extend lifespan, primarily through a significant down-regulation of genes involved in inflammation, apoptosis, angiogenesis and blood coagulation, as well as an up-regulation of genes mediating neurogenesis and nervous system system development [3]. Another recent study showed that the neuroprotective mechanism was associated with the down-regulation of metabotropic glutamate receptor-1 RNA and the inhibition of glutamate release resulting from cerebral ischemia [4].

BYHWT is one of the most classical medicinal prescriptions, comprised of seven commonly used Chinese herbs. According to the Chinese Pharmacopoeia (2005), the formula includes the following 7 herbs: (1) Radix Astragali (huangqi), the dried roots of Astragalus membranaceus (Fisch.) Bge.var. mongholicus (Bge.) Hsiao; (2) the carda part of Radix Angelicae Sinensis root (gaiqiao), the dried lateral roots of Angelica sinensis (Oliv.) Diels; (3) Radix Paeoniae Rubra (chishao), the dried roots of Paeonia lactiflora Pall.; (4) Rhizoma Chuanxiong (chauxiong), the dried rhizomes of Ligusticum chuanxiong Hort; (5) Flos Carthami (honghua), the dried flowers of Carthamus tinctoria L.; (6) Semen Persicae (taoren), the dried seeds of Amygdalus persica L.; and (7) Pheretima (dilong), the dried bodies of Pheretima aspergilum (E. Perrier), in the ratio of 120:6:4.5:3:2.5:3:3:3 on a dry
weight basis, respectively. In cases such as this, the combined effects of herbs in a multi-herbal formula may produce a powerful curative action.

Based on the theories of traditional Chinese medicine, a traditional herbal formulation contains more than single Chinese herb. Generally speaking, a traditional herbal formulation such as BYHWT is prescribed according to the principle of monarch, minister, assistant and guide. The monarch of Radix Astragali acts as the chief drug for treating the disease; the minister of Radix Angelicae Sinensis root serves to intensify the effect of the monarch drug; the assistant of Radix Paeoniae Rubra, Rhizoma Chuanxiong, Flos Carthami and Semen Persicae helps to deal with the secondary symptoms or inhibit the toxicity of the monarch drug; and the guide drug of Pheretima leads the other herbs to the diseased parts and balances the effects of all herbs.

According to the ratio of 120:6:4:5:3:3:3 on the dry herbal weight of BYHWT, Radix Astragali is the most abundant content of BYHWT and also a frequently used Chinese herb for oriental medicine. Radix astragali mainly contained the components such as saponins, isoflavone, polysaccharide and amino acid [5]. Pharmacological studies and chemical investigations of Radix Astragali have found that flavonoids and saponins are the two main types of beneficial compounds responsible for its pharmacological activities and therapeutic efficacy [6][7]. Both saponins and flavonoids should be considered as marker compounds for the qualitative and quantative analysis of Chinese medicine. It also could help to evaluate the effectiveness of this prescription and provide comprehensive quantification to ensure accuracy in clinical application.

Materials and Methods

Reagents

The authentic standards of astragaloside I, astragaloside II, formononetin, calycosin, and calycosin-7-O-β-d-glucoside were purchased from the Shanghai Tauto Biotech Co. LTD. (China) and stored at 4°C. The standard for ononin was obtained from Extrasynthese (France). Ligustilide was supplied by ChromaDex Inc. USA (10 mg/mL in acetonitrile). Paeoniflorin was from Nacalai tesque, Inc. (Kyoto, Japan). Astragaloside IV, digoxin (internal standard), pentobarbital and heparin were provided by Sigma-Aldrich Chemicals (St. Louis, MO, USA). Ammonium acetate, formic acid, acetonitrile, and methanol were of HPLC grade for analysis grade from E. Merck (Darmstadt, Germany). Triply deionized water from Millipore (Bedford, MA, USA) was prepared for all aqueous solutions.

Herbal preparation of by-yang-huan-wu-tang

The crushed herbs of Radix Astragali (1800 g), Radix Angelicae sinensis (90 g), Radix Paeoniae rubra (90 g), Rhizoma Chuanxiong (45 g), Semen Persicae (45 g), Flos Carthami (45 g), and Pheretima aspergillum (Di Long). However, in our preliminary experiments, hypoxanthine could not be observed in rat plasma after oral administration of BYHWT.

We expected that several major compounds of BYHWT extract would be detected in rat plasma after oral administration. Based on a pilot study, we finally detected nine BYHWT-related compounds in rat plasma. It can be observed that astragaloside I, astragaloside II, astragaloside IV, formononetin, ononin, calycosin, calycosin-7-O-β-d-glucoside, ligustilide and paeoniflorin were the main bioactive compounds in rat plasma after oral administration of BYHWT extract.

Several analytical methods have been developed for quantification of the target components in BYHWT, such as HPLC-DAD-ELSD coupled with HPLC-TOF/MS [13][14]. However, there are few reports available regarding pharmacokinetic studies of BYHWT. One report has previously described the analysis of multiple components of BYHWT in a pharmacokinetic study, with the determination of formononetin, ononin, calycosin, calycosin-7-O-β-d-glucoside and paeoniflorin by LC-MS [15]. However, dealing with just five constituents from one or two medicinal herbs is not corresponding with the characteristics of exhibiting effects on multiple targets. The multicomponent analysis of BYHWT, however, is not easy due to the complexity of its components.

To the best of our knowledge, no LC-MS/MS method has been reported for the simultaneous estimation of multiple constituents (i.e., flavonoids and saponins) in a single run of a conscious and freely moving rat for pharmacokinetic investigation. As a common analytical tool for various compounds, LC-MS/MS provides several advantages over LC-MS in terms of sensitivity, selectivity, etc. In this study we describe an HPLC-MS/MS assay with multiple reaction monitoring (MRM) for the measurement of nine compounds in rat plasma. This analytical method using MRM was expected to be more specific and sensitive than single-ion monitoring (SIM). Therefore, in order to simultaneously characterize and identify astragaloside I, astragaloside II, astragaloside IV, formononetin, ononin, calycosin, calycosin-7-O-β-d-glucoside, ligustilide from Radix Astragalis; ligustilide from Radix Angelicae Sinensis and Rhizoma Ligustici Chuanxiong and paeoniflorin from Radix Paeoniae Rubra, an LC-MS/MS experiment was employed to examine the specific fragmentation patterns. The applicability of these methods in assessing plasma bioactive compound following oral administration of BYHWT extract to the pharmacokinetic study in rat is also described. The pharmacokinetic study of the above components could help to elucidate the absorption mechanism of BYHWT for additional interpretation of traditional Chinese medicine. It also could help to evaluate the effectiveness of this prescription and provide comprehensive quantification to ensure accuracy in clinical application.
astragaloside IV, formononetin, ononin, caycosin, calycosin-7-O-β-D-glucoside, ligustilide and paeoniflorin in BYHWT were determined by HPLC external standard method with the analytical method (section 2.5) used in this study. The results demonstrated that the content of the constituents were quantitated in BYHWT as follows (mg/g): astragaloside I 2.46 mg/g, astragaloside II 0.69 mg/g, astragaloside IV 0.54 mg/g, formononetin 2.44 mg/g, ononin 0.63 mg/g, caycosin 0.68 mg/g, calycosin-7-O-β-D-glucoside 2.56 mg/g, ligustilide 1.08 mg/g and paeoniflorin 3.11 mg/g. The structures of astragaloside I, astragaloside II, astragaloside IV, formononetin, ononin, caycosin, calycosin-7-O-β-D-glucoside, ligustilide and paeoniflorin were shown in Fig. 1.

Freely-moving rat model
The protocol listed below has been reviewed and approved by the Institutional Animal Care and Use Committee (IACUC; approval number 1010409) by the Institutional Animal Experimentation Committee of the National Yang-Ming University. Male pathogen-free Sprague-Dawley rats (250±50 g body weight) were obtained from the Laboratory Animal Center of National Yang Ming University. The animals had free access to food (Laboratory rodent diet 5P14, PMI Feeds, Richmond, IN, USA) and water was allowed at all times. All animal experiments followed the National Yang-Ming University guidelines and procedures for the care of laboratory animals.

A freely-moving rat model was applied to minimize the stress caused by restraint or anesthesia [16]. Experimental rats were initially anesthetized with pentobarbital (50 mg/kg, i.p.), and polyethylene tubing was implanted in the right jugular vein for blood sampling. The tube crossed the subcutaneous tissue and was fixed at its exit from the dorsal neck region. The patency tubing was maintained by filling with heparinized saline (20 units/mL). After surgery, the rats were placed in experimental cages and allowed to recuperate for one day. The rats were kept fasted for 12 h and water were available ad libitum before the BYHWT administration.

Oral administration and sample preparation
BYHWT extract was dissolved in normal saline at doses of 10 g/kg for oral administration and fed by gavages to rats, respectively. The dosage of BYHWT was selected by the indication of concentrated herbal extracts (powdered) for clinical application which was 3.5 g each time and 3–4 times daily in adults. According to the dose translation from animal to human studies [17], we used the body surface area (BSA) normalization method to convert the dose of nine active compounds for translation from humans to rat. In our study, the dose of BYHWT (10 g/kg) was appropriate for oral administration in rats. An aliquot of 100–120 μL blood sample was withdrawn from the jugular vein into a heparin-rinsed vial with a fraction collector according to a programmed schedule at 5, 15, 30, 45, 60, 90, 120, 150, 180, 240, 300, 360, 480, 600 and 720 min. The condensed

Figure 1. Structure formula of 9 components in bu-yang-huan-wu-tang extract of astragaloside I (A), astragaloside II (B), astragaloside IV (C), formononetin (D), ononin (E), caycosin (F), calycosin-7-O-β-D-glucoside (G), ligustilide (H) and paeoniflorin (I). doi:10.1371/journal.pone.0043848.g001
blood collection in the absorption phase is to figure out the maximum concentration and the time when it reaches the maximum concentration. The time points in the elimination phase are not close. This strategy is commonly used in the pharmacokinetic studies but the total blood consumption should not be over 20% of body blood. In these experimental rats, the total blood sampling volume is within 20% during 12 h [18]. Plasma was separated by centrifuging the blood sample at 6000 rpm for 10 min at 4°C. The plasma samples (50 μL) were vortex-mixed with double volume (100 μL) of acetonitrile containing digoxin (100 ng/mL) as the internal standard for protein precipitation. The samples were vortexed and centrifuged at 16,100×g for 10 min. In our micro-analysis, less than 200 μL is needed. Actually, the collected blood volume is around 120–150 μL for each time point. After centrifugation, the plasma samples (50 μL) were vortex-mixed with 100 μL of acetonitrile. The supernatants were collected and filtered. Around 20 μL aliquot of the supernatants was transferred into the vial for analysis by HPLC-MS/MS system. The acetonitrile but not the real sample was used in the needle pre-wash standard procedure [10][19].

Liquid chromatography–tandem mass spectrometry

The LC-MS/MS system consisted of an Agilent 1100 series LC with automatic liquid chromatographic sampler, injector, bi-pump and degasser; and Applied Biosystems/MDS Sciex API 3000 tandem quadrupole mass spectrometry equipped with electrospray ionization [ESI] interface using the following parameters: nebulizer gas (NEB):10, curtain gas (CUR): 7, collisionally activated dissociation gas (CAD): 12, ionspray voltage (IS): 5000 V, turbo ionspray temperature (TEM): 450°C. Nitrogen was used in all cases. The mass spectrometer was operated in the positive ion detection mode. Analytes were quantified by multiple-reaction monitoring [MRM] mode performing the following precursor-to-product ion pairs of the transitions m/z: m/z 886.6 [M+NH₄]⁺→m/z 143.2 for astragaloside I (dechlorination potential 55 V, focusing potential 290 V, entrance potential 12 V, collision energy 23 V, collision cell exit potential 13 V); m/z 844.5 [M+NH₄]⁺→m/z 143.2 for astragaloside II (DP 62 V, FP 330 V, EP 13 V, CE 25 V, CXP 13 V); m/z 802.6 [M+NH₄]⁺→m/z 143.2 for astragaloside IV (DP 65 V, FP 370 V, EP 14 V, CE 28 V, CXP 10 V); m/z 269.2 [M+H]⁺→m/z 253.2 for formononetin (DP 190 V, FP 380 V, EP 14 V, CE 37 V, CXP 16 V); m/z 431.3 [M+H]⁺→m/z 269.2 for ononin (DP 80 V, FP 380 V, EP 13 V, CE 20 V, CXP 18 V); m/z 285.2 [M+H]⁺→m/z 270.2 for calycosin (DP 190 V, FP 380 V, EP 13 V, CE 35 V, CXP 17 V); m/z 447.2 [M+H]⁺→m/z 285.1 for Calycosin-7-O-β-D-glucoside (DP 80 V, FP 380 V, EP 12 V, CE 23 V, CXP 19 V); m/z 208.1 [M+NH₄]⁺→m/z 173.2 for ligustilide (DP 70 V, FP 380 V, EP 14 V, CE 25 V, CXP 12 V); m/z 498.3 [M+NH₄]⁺→m/z 179.2 for paoniflorin (DP 76 V, FP 390 V, EP 14 V, CE 25 V, CXP 12 V) and m/z 798.6 [M+NH₄]⁺→m/z 651.6 for digoxin (DP 20 V, FP 160 V, EP 10 V, CE 18 V, CXP 11 V, internal standard). Nine active constituents and the internal standard were separated by using a Phenomenex® Gemini C18 (150 mm×2.0 mm I.D, 5 μm particles) column maintained at ambient temperature. The following linear gradient program was applied to the analyte with the mobile phase consisting of methanol (0.1% formic acid, solvent A) and NH₄HAc (0.1% formic acid, solvent B); 0–1 min: 30–70% A; 1–2 min 70–90%; 2–3 min; 90–90%; 8–9 min; 90–90%, 9–18 min: 30–30%, v/v. The sample injection volume was 10 μL. The flow rate was maintained at 0.2 μL/min.

Preparation of calibration standards

The stock standard solution containing astragaloside I (1 mg/mL), astragaloside II (1 mg/mL), formononetin (1 mg/mL), ononin (1 mg/mL), calycosin (1 mg/mL), calycosin-7-O-β-D-glucoside (1 mg/mL) and paoniflorin (1 mg/mL) was prepared in methanol. The standard powder of astragaloside IV was dissolved in 50% (v/v) acetonitrile to make a 1 mg/mL stock solution, and ligustilide was prepared in 100% acetonitrile for a 10 mg/mL stock solution. The internal standard stock solution of 1 mg/mL was also dissolved in 50% (v/v) acetonitrile. All solutions were stored at −20°C before use. These solutions were further diluted to give a serial of working standard solutions and samples for calibration in plasma were prepared by spiking aliquots of the stock solutions into drug-free plasma samples to obtain final concentrations in the range of 0.5–100 ng/mL for astragaloside I, astragaloside II, astragaloside IV, ononin; 5–1000 ng/mL for formononetin; 5–100 ng/mL for calycosin; 1–100 ng/mL for calycosin-7-O-β-D-glucoside, ligustilide and 0.5–1000 ng/mL for paoniflorin, and then processed according to the procedures described in Section 2.4.2. The validation samples were also prepared in the same way (1, 10, 100 ng/mL for astragaloside I, astragaloside II, astragaloside IV, ononin calycosin-7-O-β-D-glucoside, ligustilide; 10, 100, 1000 ng/mL for formononetin, calycosin, paoniflorin) at low, middle and high concentrations.

Method validation

Full validation of the analytical method evaluated in this study was according to the US Food and Drug Administration guidelines for validation of bioanalytical methods [20]. Full validation was performed for determination of analyte samples in this study. Specificity, sensitivity, linearity, precision, accuracy, recovery, matrix effect, and stability were evaluated during the method validation.

The specificity was assessed by confirming the blank plasma extract for the presence or absence of interference as well as the lot-to-lot variation regarding interference. Sensitivity of analytes was determined by calculating the signal-to-noise ratio of lowest limit of quantitation (LOQ) samples. The limits of detection (LOD) and quantitation (LOQ) were determined at S/N (the ratio of signal to noise) of 3 and 10 under the present chromatographic conditions. The calibration standard curves were obtained by least-squares linear regression of the peak area versus the concentrations. All calibration curves were required to have a correlation value of at least 0.995. The concentration of each sample was derived from the calibration curve and corrected by the respective dilution volume. For a standard curve, the ratios of the chromatographic peaks area [analytes/internal standard] as ordinate variables were plotted versus the concentration of these drugs as abscissa. The samples in six replicates on the same day (intra-day) and on six successive days (inter-day) were prepared in the same manner to verify the precision and accuracy of the analytical method. The accuracy was calculated from the nominal concentration (Cnom) and the mean value of observed concentration (Cobs) as follows: accuracy (bias, %) = |Cnom−Cobs|/Cnom×100. The precision (relative standard deviation, RSD) was calculated from the standard deviation and observed concentration as follows: precision (RSD, %) = [standard deviation (SD)/Cobs]×100. The inter-day and intra-day accuracy and precision value for the lowest acceptable reproducibility concentrations were defined as being within ±15%. The LLOQ was defined as which the signal/noise ratio was ≥10 and the accuracy and precision were within 80–120%.
The matrix effect was determined at low, medium and high concentrations using three replicates as the ratio of the mean peak area of an analyte spiked post-extraction (set 2) to the mean peak area of the same analyte standards (set 1)×100%. The extraction recovery of analytes were determined at three concentrations by calculating as the ratio of the mean peak area of an analyte spiked before extraction (set 3) to the mean peak area of an analyte spiked post-extraction (set 2)×100%.

Stability was also assessed using the low, medium and high concentrations of analytes. Freeze-thaw stability was assessed over three freeze-thaw cycles. Short-term stability was determined by placing the samples at room temperature for 6 h. Long-term stability was evaluated by analyzing samples kept at -20°C for 14 days. Autosampler stability was determined by maintaining the samples at the autosampler temperature (8°C) for 12 h. All stabilities were calculating as the ratio of average concentration and freshly prepared samples.

Pharmacokinetic application
Pharmacokinetic parameters including maximum plasma concentration (Cmax), time to reach the maximum concentrations (Tmax), half-life (t1/2), area under concentration-time curve (AUC) and oral clearance (CL) were estimated by a non-compartmental analysis using the pharmacokinetic program, WinNonlin Standard Edition Version 1.1 (Scientific Consulting, Apex, NC, USA). All results were expressed as average mean ± standard deviation (S.D.). ANOVA was used to evaluate differences, and a value of P<0.05 was taken as statistically significant.

Results and Discussion
Chromatographic and tandem mass spectrometric condition
Owing to the complexity of traditional Chinese medicine, many analogues may be co-eluted during analyses. In order to develop a sensitive and accurate LC-MS/MS method for the determination of BYHWT active compounds in rat plasma, a triple quadrupole mass spectrometer equipped with electrospray ionization (ESI) source is currently one of the most useful tools available for simultaneous quantification of herbal compounds because of its high sensitivity and selectivity. Qualification analysis was performed using an MRM system consisting of two parts: selecting the precursor ion (MS 1) and selecting a specific fragment of precursor ion (MS 2). These two devices generate a very specific and sensitive response for the selected analyte. Thus the integrated peak for the target compound could be monitored in a sample after a simple one dimensional chromatographic separation. The determination of nine active compounds and internal standard were performed by positive mode ESI-MS/MS since higher ion intensities were observed using positive relative to negative mode.

To characterize the fragment ions of the investigated compounds, an electrospray interface with good sensitivity, fragmentation and linearity was optimized.

The astragaloside profiles of astragaloside I, astragaloside II and astragaloside IV in the Radix Astragali could be observed. However, due to the complexity of the extract and the similar structures of astragalosides, it has been noted that these peaks require careful identification and separation [21]. Astragaloside I produced a positive ion of m/z 886.6, corresponding to the [M+H]+ precursor ions. The succeeding product ion of the precursor ion produced a fragmentation pattern lead to an ion at m/z 143.2. In addition, the mass transit ion patterns m/z 844.5→143.2 and m/z 802.6→143.2 were selected to monitor astragaloside II and astragaloside IV, respectively.

For isoflavonoids, the chemical structure of formononetin is similar to that of calycosin, differing in the substituent group located on a ring with a hydroxyl group [22]. The behavior of calycosin fragmentation could be extended to other isoflavones; and the protonated isoflavone aglycones reveal that the loss of a methyl radical was the predominant fragmentation for the aglycones, due to the formation of very stable cation radical structures. The major product ion of m/z 253.2 for formononetin may be due to the loss of a hydroxyl group. The compounds ononin and calycosin-7-O-β-d-glucoside are O-glycosides. In positive ion mode, the glycosidic bond of O-glycosides was easily cleaved to produce daughter ions of [M+H−162]+ at 269.2 and 285.1 by the facile neutral loss of a glucose residue from the corresponding protonated molecule ions at 431.3 and 447.2, respectively. The major product ions of liguistilide in Radix Angelicae Sinensis and Rhizoma Ligustici Chuanxiong at 173.2 corresponded to one hydroxyl group loss from the precursor ion. The major product ion of m/z 179.2 for paeoniflorin in Radix Paeoniae Rubra may be due to the loss of a glucose molecule, a benzoic acid molecule and a hydrone molecule [23]. The main fragments of the BYHWT active component are listed in Table 1. The MS/MS parameters manually obtained the highest response for each of the precursor and product ion combinations.

In this developed method, the degree of interference was assessed by inspection of MRM mode. No significant interfering peaks from the plasma were found at the retention time and the ion channel of either the analytes or internal standard. Hence the development of the chromatographic system was concentrated on short retention times substituted for chromatographic separation. As shown in Fig. 2, the 9 selected marker compounds with IS cover a broad polarized range. The gradient elution, proper column and flow rate were pivotal influences on separation for multi-compounds. The chromatographic conditions achieved good resolution and appropriate ionization in the presence of endogenous species and co-elution. The chemical structures of astragalosides and internal standard have been noted as being relatively stable to acids [24]. To improve the sensitivity, adding acid to the mobile phase to enhance the ionization of astragalo-sides has also been suggested. It was also discovered that addition of 0.1% formic acid in the mobile phase provided a higher response and better peak sensitivity. In the course of the current study, several mobile phase systems, such as acetonitrile-water and methanol-water, in different ratios were examined. The acetonitrile-water system provides good separation for the investigated compounds, but the ligustilide peak had serious interference in the chromatogram. Finally, methanol-NH4OAc with 0.1% formic acid was employed, providing an appropriate retention time and low background noise, and was thus selected as the mobile phase system.

Ideally, a compound with similar physical-chemical properties should be used as the internal standard for analysis. Digoxin, which has a chemical structure similar to astragaloside I, astragaloside II and astragaloside IV, was chosen as the internal standard in the quantitative method in plasma. This compound was consistent with investigated analytes in chromatographic recovery and ionization properties. With extensive separation and optimization, the conditions established for reference compounds could be eluted with baseline separation in approximately 18 min. Under the proposed conditions, the electrospray ion mass spectrometer was used for quantitative analysis.
The precision and accuracy of the method were assessed in plasma by performing replicate analyses of spiked samples against calibration standards. The procedures were repeated on the same day and between six different days on the spiked samples with low, middle and high concentrations. The intra-day and inter-day precision and accuracy of the method are shown in Table 2. The precisions (relative standard deviation; RSD) were all less than 10%. The data indicated that the precision and accuracy of this method were acceptable.

Matrix effect and recovery

The extraction recoveries and matrix effect from rat plasma are shown in Table 3. The one-step extraction procedure was fairly rapid. The protein precipitation by the organic solvent, acetonitrile (0.1% formic acid) was used to prepare the plasma samples for LC-MS/MS. Co-eluting compounds may enhance or suppress the ionization of the analytes. Owing to the sample preparation of the biological matrix (protein precipitation), matrix effects were expected. In order to avoid these matrix effects, good separation of the analytes was pursued. To measure the matrix effect, it was determined at three different concentrations for all analytes. An absolute matrix effect was observed for some of the analytes at some of the low, middle and high concentrations. Nevertheless, no relative matrix effects were seen, since the coefficients of variation (CV %) at each concentration level were <15% for all compounds. The extraction recoveries were also determined for three replicates from rat plasma spiked with low, middle and high concentrations of the nine analytes and internal standard. The mean recoveries of most samples were within 80–120%, except for astragaloside II. The recoveries of astragaloside II were 79.9±12% and 76.3±5.7% at concentration of 10 ng/mL and 100 ng/mL. Even it was slightly out of range, the extraction recovery of astragaloside II was stable and there was no other significant interference over the range.

Stability

To estimate the stability of extracted samples during the experiments, storage, and sample preparation processes were designed and conducted under different conditions, including freeze-thaw cycle analysis, short-term stability, long-term stability and autosampler stability by analysis using biological samples. Deviation of the mean measured concentrations of the samples from the nominal concentration was within 15%. All established stabilities for nine active compounds are shown in Table 4. The

| Compounds               | Molecular weight | RT (min) | Mass fragments          |
|-------------------------|------------------|----------|-------------------------|
|                         |                  |          | Q1 Mass (amu) | Q3 Mass (amu) |
| Astragaloside I         | 869.04           | 11.21    | 886.6 [M+NH4]+     | 143.2        |
| Astragaloside II        | 827.01           | 10.73    | 844.5 [M+NH4]+     | 143.2        |
| Astragaloside IV        | 784.97           | 11.18    | 802.6 [M+NH4]+     | 143.2        |
| Formononetin            | 268.26           | 8.32     | 269.2 [M+H]+       | 253.2        |
| Ononin                  | 430              | 8.23     | 431.3 [M+H]+       | 269.2        |
| Calycosin               | 284.2            | 8.72     | 285.2 [M+H]+       | 270.2        |
| Calycosin-7-O-β-D-glucoside | 446.4          | 7.68     | 447.2 [M+H]+       | 285.1        |
| Ligustilide             | 190.24           | 10.05    | 208.1 [M+NH4]+     | 173.2        |
| Paeoniflorin            | 480.47           | 7.37     | 498.3 [M+NH4]+     | 179.2        |
| Digoxin (IS)            | 780.94           | 9.12     | 798.6 [M+NH4]+     | 651.6        |

doi:10.1371/journal.pone.0043848.t001
Pharmacokinetics of Herbal Formulation
stability of freeze-thaw cycle analysis, short-term and autosampler remained generally stable under the analyte storage and analytical process conditions. The long-term tests showed little variation compared to the initial concentration in astragaloside I (100 ng/mL), calycosin (100, 1000 ng/mL), Calycosin-7-O-β-D-glucoside (10, 100 ng/mL), ligustilide (100 ng/mL) and paoniflorin (10, 1000 ng/mL). These observations indicate that testing must be executed after the sample extraction. Based on the above method validation, the processes for the analysis of these herbal ingredients were acceptable.

Table 2. Intra-day and inter-day precision and accuracy for the determination for nine compounds from the assay samples (n = 6).

| Nominal concentration (ng/mL) | Intra-day | Inter-day |
|------------------------------|-----------|-----------|
|                              | Observed concentration (ng/mL) | Precision (%) | Accuracy (%) | Observed concentration (ng/mL) | Precision (%) | Accuracy (%) |
| Astragaloside I              | 1         | 1.14±0.1  | 5.3         | 4.2 | 0.92±0.2  | 6.1         | 1.1        |
|                              | 10        | 11.2±2.7  | 4.2         | −1.9 | 11.1±2.9  | 4.3         | −1.3       |
|                              | 100       | 99.4±6.8  | 4.1         | −3.3 | 99.8±7.1  | 4.6         | 0.8        |
| Astragaloside II             | 1         | 1.22±0.3  | 7.2         | 2.2 | 1.1±0.8   | 5.5         | 1.3        |
|                              | 10        | 10.3±3.0  | 5.5         | −1.8 | 11.0±3.1  | 3.2         | −1.2       |
|                              | 100       | 102±6.4   | 4.9         | 1.5 | 101±5.4   | 2.8         | 0.2        |
| Astragaloside IV             | 1         | 1.31±0.3  | 3.9         | 1.4 | 9.91±0.3  | 7.9         | 1.9        |
|                              | 10        | 11.0±2.3  | 4.1         | 2.8 | 11.2±2.1  | 3.0         | 0.2        |
|                              | 100       | 98.4±4.4  | 2.5         | 1.9 | 102±4.6   | 1.7         | 1.8        |
| Formononetin                 | 10        | 11.0±2.3  | 5.6         | 2.7 | 9.37±1.9  | 2.8         | 3.2        |
|                              | 100       | 99.1±4.2  | 4.9         | 1.3 | 98.6±5.5  | 4.3         | −1.1       |
|                              | 1000      | 998±18.2  | 2.9         | 1.8 | 1002±16.2 | 3.1         | 0.4        |
| Ononin                       | 1         | 0.95±0.4  | 3.6         | 2.7 | 0.93±1.7  | 4.9         | 0.9        |
|                              | 10        | 10.5±2.8  | 2.8         | −1.1 | 10.5±2.1  | 3.4         | −0.2       |
|                              | 100       | 98.8±3.2  | 2.9         | 0.4 | 99.2±2.7  | 2.9         | 1.3        |
| Calycosin                    | 10        | 10.2±1.1  | 6.4         | 2.5 | 9.67±1.3  | 5.4         | 4.8        |
|                              | 100       | 101±5.2   | 4.1         | 1.0 | 99.3±4.6  | 2.1         | 2.1        |
|                              | 1000      | 1005±7.1  | 4.8         | 0.9 | 1004±9.8  | 3.7         | 1.9        |
| Calycosin-7-O-β-D-glucoside  | 1         | 1.11±0.7  | 5.2         | 2.3 | 0.96±0.4  | 2.6         | 1.8        |
|                              | 10        | 10.8±2.1  | 3.3         | −1.1 | 10.2±1.6  | 3.3         | −0.7       |
|                              | 100       | 98.4±5.7  | 2.8         | 2.8 | 101.4±43.3 | 1.2        | 0.3        |
| Ligustilide                  | 1         | 0.92±0.4  | 4.9         | 0.3 | 1.03±0.2  | 3.8         | 2.1        |
|                              | 10        | 10.2±2.1  | 0.5         | 0.3 | 9.43±1.7  | 4.1         | −0.9       |
|                              | 100       | 97.3±5.5  | 3.6         | −0.4 | 98.3±5.6  | 1.7         | 1.1        |
| Paeoniflorin                 | 10        | 9.60±0.77 | 5.7         | −1.1 | 11.3±0.4  | 0.9         | 1.1        |
|                              | 100       | 97.3±7.64 | 7.4         | 0.2 | 10.8±3.9  | −0.6        | −0.3       |
|                              | 1000      | 1008±42.5 | 4.7         | 0.3 | 1006±16   | 0.1         | −3.6       |

doi:10.1371/journal.pone.0043848.t002
**Table 3.** Extraction recovery and matrix effect of nine compounds and internal standard in rat plasma.

| Compounds               | Set 1<sup>a</sup> | Set 2<sup>b</sup> | Set 3<sup>c</sup> | Matrix effect (%)<sup>d</sup> | Recovery (%)<sup>e</sup> |
|-------------------------|-------------------|-------------------|-------------------|-----------------------------|--------------------------|
| Astragaloside I         |                   |                   |                   |                             |                          |
| 1                       | 1.08±0.1          | 1.03±0.4          | 1.08±0.4          | 95.5±12                     | 105±6.2                  |
| 10                      | 10.2±1.2          | 8.67±2.8          | 7.62±1.2          | 85.0±7.6                    | 87.9±12                  |
| 100                     | 99.7±5.3          | 74.3±7.5          | 77.3±5.8          | 74.5±1.5                    | 104±14                   |
| Astragaloside II        |                   |                   |                   |                             |                          |
| 1                       | 1.24±0.2          | 1.00±0.1          | 0.88±0.3          | 80.9±7.4                    | 87.4±6.0                 |
| 10                      | 10.8±0.6          | 9.63±1.5          | 7.70±2.0          | 89.2±6.8                    | 79.9±12                  |
| 100                     | 101±3.2           | 80.9±6.3          | 61.7±4.9          | 80.1±13                     | 76.3±5.7                 |
| Astragaloside IV        |                   |                   |                   |                             |                          |
| 1                       | 1.28±0.2          | 1.16±0.5          | 1.12±0.3          | 90.4±1.4                    | 96.3±2.6                 |
| 10                      | 9.81±1.3          | 11.1±2.4          | 10.8±3.2          | 113±4.3                     | 97.7±9.4                 |
| 100                     | 98.2±5.8          | 105±4.2           | 99.4±3.9          | 107±8.1                     | 94.6±9.4                 |
| Formononetin            |                   |                   |                   |                             |                          |
| 10                      | 11.4±2.3          | 12.0±1.2          | 10.5±2.1          | 105±6.9                     | 87.9±12                  |
| 100                     | 101±4.2           | 99.1±5.3          | 92.1±6.0          | 98.1±5.6                    | 92.9±9.5                 |
| 1000                    | 995±11            | 918±14            | 898±20            | 92.3±5.9                    | 97.8±0.2                 |
| Ononin                  |                   |                   |                   |                             |                          |
| 1                       | 0.98±0.2          | 0.93±0.3          | 0.86±0.1          | 94.8±7.5                    | 92.2±6.0                 |
| 10                      | 11.2±1.3          | 10.6±2.9          | 10.6±2.2          | 94.9±9.5                    | 100±2.6                  |
| 100                     | 97.9±5.2          | 96.4±6.3          | 90.8±3.9          | 98.5±8.2                    | 94.2±8.7                 |
| Calycosin               |                   |                   |                   |                             |                          |
| 10                      | 11.1±2.2          | 12.3±2.3          | 11.7±1.8          | 111±3.3                     | 95.1±3.3                 |
| 100                     | 97.8±4.4          | 105±5.8           | 97.9±6.3          | 107±8.0                     | 93.5±2.3                 |
| 1000                    | 997±8.8           | 1056±20           | 1056±23           | 106±10.1                    | 100±0.2                  |
| Calycosin-7-O-[D]-glucoside |             |                   |                   |                             |                          |
| 1                       | 1.19±0.3          | 0.95±0.4          | 0.83±0.2          | 80.0±8.7                    | 87.6±8.3                 |
| 10                      | 9.86±1.3          | 9.69±2.1          | 9.39±1.4          | 98.3±8.2                    | 96.9±0.9                 |
| 100                     | 98.7±4.3          | 97.9±6.7          | 93.8±8.2          | 99.2±4.4                    | 95.8±7.1                 |
| Ligustilide             |                   |                   |                   |                             |                          |
| 1                       | 0.97±0.5          | 0.93±0.1          | 0.90±0.3          | 95.7±10                     | 97.3±3.1                 |
| 10                      | 11.4±1.1          | 11.8±2.7          | 11.3±0.4          | 103.8±5.7                   | 95.5±9.9                 |
| 100                     | 99.3±7.1          | 98.8±9.3          | 95.1±6.2          | 99.5±7.5                    | 96.2±1.9                 |
| Paeoniflorin            |                   |                   |                   |                             |                          |
| 10                      | 10.2±1.7          | 10.4±2.3          | 11.0±2.9          | 102±9.0                     | 106±5.2                  |
| 100                     | 98.8±3.9          | 98.8±6.2          | 94.7±4.6          | 100±7.7                     | 95.8±4.2                 |
| 1000                    | 995±17            | 991±11            | 966±15            | 99.6±14                     | 97.5±3.8                 |
| Digoxin (IS)            |                   |                   |                   |                             |                          |
| 66.7                    | 64.3±4.4          | 65.5±5.3          | 65.6±4.7          | 102±5.2                     | 100±4.2                  |

Data are expressed as means ± S.D. (n = 3).

<sup>a</sup>Neat is the standard in injection solvent.

<sup>b</sup>Post-spiked is the standard spiked in the prepared control plasma.

<sup>c</sup>Pre-spiked is the standard spiked into control plasma before prepared.

<sup>d</sup>Matrix effect (%) calculated as [(b/a)×100]%.

<sup>e</sup>Recovery (%) calculated as [(c/b)×100]%.

doi:10.1371/journal.pone.0043848.t003

**Application of the analytical system in pharmacokinetics study**

The validated HPLC-MS/MS method was successfully applied for the simultaneous determination of nine active constituents for 12 h after BYHWT extract administration (10 g/kg, p.o.) in the rat. The mean plasma concentration-time profiles are illustrated in Fig. 3 and the pharmacokinetic parameters are presented in Table 5.

The concentration-time curves of astragaloside I, astragaloside II, astragaloside IV and ligustilide presented the phenomenon of a double-peak absorption phase in the plasma profile, and the other analytes seemed to have the same tendency. However, the other herbal ingredients of formononetin, ononin, calycosin, calycosin-7-
O-β-D-glucoside and paoniflorin presented a single and plateau absorption phase, consistent with a previous report [15]. By means of plateau absorption or multiple-peak absorption phase, these phenomena were similar to another report on Chinese herbal compounds [25]. There were many possible explanations that attempt to explain the phenomenon of multiple-peak behavior. Similar multiple-peak phenomena have been observed in a number of other oral drugs [26][27]. Several mechanisms have been proposed for the phenomenon: 1) enterohepatic recycling, the cycle in which bile salts and drugs excreted by the liver are absorbed by the intestinal mucosa and returned to the liver via the portal circulation [28]. 2) the presence of absorption sites along the stomach and different gastrointestinal segments [29]. 3) variable gastric emptying; a previous report suggests that the drug may cause increased gastric pH which in turn increases the gastric emptying rate [30]. After increasing the gastric emptying rate, a substantial amount of drug emptied into the duodenum soon after the administration can cause a rapid increase in plasma concentrations, resulting in the disappearance of double peaks [31].

Herbal preparation is a complex formulation which contains several herbs and ingredients. It is possible that the different characteristics of physical-chemical properties for individual ingredients may affect each other. In an in vitro herbal analysis,
it is indicated that the berberine content in herbal preparation of Huang-Lian-Jie-Dwu-Tang (8.15 ± 0.39 mg/g) was less in the single herb Coptidis Radix (53.63 ± 2.45 mg/g) but higher in Phellodendri Cortex (3.02 ± 0.22 mg/g) when extracted with water, which suggest that herbal matrix effects were involved in the multiple compositions of the herbal preparation [32]. Another in vivo experiment discussed the pharmacokinetic of single herbal ingredient, single herbal extract and herbal preparation. Rutacarpine (25 mg/kg/day, p.o.) (the herbal ingredient of Evodia rutaecarpa), the ethanol extract of Evodia rutaecarpa (1 g/kg/day).

**Table 5.** Pharmacokinetic parameters of the nine compounds in rat after oral administration of bu-yang-huan-wu-tang.

| Parameter                | C<sub>max</sub> (ng/mL) | T<sub>max</sub> (min) | t<sub>1/2</sub> (min) | AUC (min mg/mL) | Cl (mL/min/kg) |
|--------------------------|-------------------------|----------------------|----------------------|-----------------|----------------|
| Astragaloside I          | 55 ± 7.8                | 40 ± 16              | 166 ± 28             | 16.6 ± 2.6      | 90.5 ± 14      |
| Astragaloside II         | 30 ± 4.9                | 37 ± 6.8             | 212 ± 14             | 11.4 ± 2.3      | 129 ± 15       |
| Astragaloside IV         | 100 ± 16                | 35 ± 7.7             | 170 ± 8.3            | 23.0 ± 5.7      | 64.3 ± 13      |
| Formononetin             | 98 ± 17                 | 38 ± 8.2             | 175 ± 13             | 26.7 ± 6.0      | 57.4 ± 14      |
| Ononin                   | 19 ± 4.5                | 35 ± 7.7             | 134 ± 9.6            | 4.6 ± 1.0       | 351 ± 47       |
| Calycosin                | 123 ± 17 ± 13           | 40 ± 16              | 75 ± 11              | 308 ± 73<sup>b</sup> | 5.4 ± 1.3   |
| Calycosin-7-O-β-D-glucoside | 18 ± 4.1              | 32 ± 6.1             | 338 ± 132            | 3.25 ± 0.7      | 428 ± 143     |
| Ligustilide              | 7.8 ± 0.2               | 45 ± 0.0             | 267 ± 1.2            | 2.43 ± 0.06     | 532 ± 11       |
| Paeoniflorin             | 97 ± 33                 | 35 ± 7.7             | 93 ± 32              | 21.0 ± 3.9      | 76.5 ± 15      |

Data expressed as mean ± standard error. (n = 6) C<sub>max</sub>: the maximum plasma concentration, t<sub>1/2</sub>: half-life, AUC: area under the concentration-time curve, Cl: clearance. 
<sup>a</sup>Significantly different (p < 0.05) from the other active compounds in C<sub>max</sub>. 
<sup>b</sup>Significantly different (p < 0.05) from the other active compounds in AUC.

doi:10.1371/journal.pone.0043848.t005
p.o.) and multiple herbal preparation of Evodia rutacarpa ( Wu-Chu-Yu-Tang; 1 g/kg/day, p.o.) were individually pretreated daily for three consecutive days in rats and caffeine was administered (2 mg/kg, i.v.) on the fourth day. The results indicate that the rutacearpine (single ingredient), extract of Evodia rutacarpa, and herbal preparation (Wu-Chu-Yu-Tang) provide significant interaction for the pharmacokinetics of caffeine [33].

Rat is anatomically lack of gall bladder and the bile juice is directly excreted into duodenum. A previous biliary excretion report indicates that the gastrodin (an active substance isolated from Gastrodia eleta Blume) and its metabolite have been detected in the bile duct [34]. Another pair-rats experimental model is designed to investigate the enterohepatic circulation of colchicine [35]. The results show that the AUC of colchicine was 847.7±141.0 and 55.5±29.2 min µg/mL in the donor and recipient rats, respectively. The biliary excretion and enterohepatic circulation may have significant effects on the pharmacokinetics of a number of drugs. Our data demonstrate that the double-peak phenomenon in the pharmacokinetic curve may be caused by the biliary excretion and enterohepatic circulation. However, this is the first reported case of double peaks for BYHWT absorption. The double-peak phenomenon caused by the hypothesized mechanism may have important therapeutic and drug interaction implications, especially because traditional medicines are commonly coadministered with other drugs. Furthermore, studies are needed to investigate the mechanism underlying the double-peak phenomenon for BYHWT with its active components in the future.

The cycloartan-type triterpene glycosides group in Radix Astragali of astragaloside I, astragaloside II and astragaloside IV, which were comprised of the same aglycone cycloastragenol and only differ in number and position of glucosyl, but their pharmacokinetic behaviors were significant different. The contents of astragaloside I, astragaloside II and astragaloside IV in the herbal preparation of BYHWT were 2.46, 0.69 and 0.54 mg/g, respectively. However, the values of Cmax and AUC of astragaloside I and astragaloside II were much lower than astragaloside IV. This phenomenon might be referred to the biotransformation of astragaloside I to astragaloside IV about intestinal bacteria and enzymatic reaction, arising from great increase of astragaloside IV in vivo. Moreover, the contents in herbal preparations may be the substrates of inhibitors, or inducers of Cytochromal enzymes, and hence had individual or combination effects on the pharmacokinetics of each other [36].

Calyosin displayed rapid and sustained absorption, with the largest Cmax at 1231±171 ng/mL (p<0.05) and AUC at 308±73 min mg/mL (p<0.05); and at 5±11, calyosin had the shortest elimination half-life min among nine tested compounds of BYHWT. Formononetin had second largest amount of AUC value, perhaps due to its structural similarity to calyosin. Ononin and calyosin-7-O-β-d-glucoside had identical pharmacokinetic parameters in organisms, with their Cmax and T max being similar and both of them having low AUC. However, the BYHWT contents of ononin and calyosin-7-O-β-d-glucoside in were 0.63 and 2.56 mg/g, respectively, since the ononin content in plasma was higher. This might be ascribed to the relatively weak polarity of ononin.

Ligustilide is one of the most important bioactive components of Radix Angelicae Sinensis and Rhizoma Ligustici Chaumxiang, and paeoniflorin is the major bioactive ingredient in Radix Paeoniae Rubra in BYHWT. Significantly, the amounts of crude drug of Radix Angelicae Sinensis and Rhizoma Ligustici Chaumxiang in BYHWT were much higher than that of Radix Paeoniae Rubra. But there was less ligustilide than paeoniflorin found in the quantitative results, and our findings indicated that the Cmax and AUC of ligustilide were much lower than paeoniflorin in a living organism. Moreover, the extent and rate of drug uptakes into the systemic circulation of AUC and Cmax for ligustilide were the lowest in BYHWT. However, the previous report did not monitor ligustilide as one of their target components [15]. In this study, we provide more detailed information to enable better understanding for the pharmacokinetic profiles of the herbal preparation BYHWT. Moreover, based on the interpretation of pharmacokinetic profiles for the individual herbal ingredients, the pharmacokinetic characteristics of this complicated traditional Chinese herbal preparation might be gradually revealed.

Conclusion

In present study, reliable high-performance liquid chromatography coupled with tandem mass spectrometry was successfully used for the quantitation of bioactive compounds of astragaloside I, astragaloside II, astragaloside IV, formononetin, ononin, calyosin, calyosin-7-O-β-d-glucoside, ligustilide and paeoniflorin in rat plasma after oral administration of BYHWT. These pharmacokinetic studies were performed through an experimental model of freely moving rats. The assay provided adequate recovery and matrix effect with good precision and accuracy. These pharmacokinetic results provide a constructive contribution to better understand the extensive action mechanism of absorption, distribution, metabolism and excretion, and to prepare for future clinical evaluation.

Author Contributions

Conceived and designed the experiments: LHS THT. Performed the experiments: LHS LCL THT. Analyzed the data: LHS THT. Contributed reagents/materials/analysis tools: LHS LCL THT. Wrote the paper: LHS THT. Herbal preparation: LHS LCL.

References

1. Zhang H, Wang WR, Lin R, Zhang JY, Ji QL, et al. (2010) Buyang Huanwu decoction ameliorates coronary heart disease with Qi deficiency and blood stasis syndrome by reducing CRP and CD40 in rats. J Ethnopharmacol 130: 99–102.
2. Wang WR, Lin R, Zhang H, Lin QQ, Yang LN, et al. (2011) The effects of Buyang Huanwu Decoction on hemorheological disorders and energy metabolism in rats with coronary heart disease. J Ethnopharmacol 137: 214–220.
3. Wang HW, Liou KT, Wang YH, Lo CK, Lin YL, et al. (2011) Deciphering the neuroprotective mechanisms of Buyang-Huanwu decoction by an integrative neurofunctional and genomic approach in ischemic stroke mice. J Ethnopharmacol 138: 22–33.
4. Zhao LD, Wang BH, Jin GR, Zhao Y, Zhang HJ (2012) Neuroprotective effect of Buyang Huanwu decoction against focal cerebral ischemia/reperfusion injury in rats–time window and mechanism. J Ethnopharmacol 140: 339–344.
5. Qi LW, Yu QT, Yi L, Ren MT, Wen XD, et al. (2008) Simultaneous determination of 15 marker constituents in various radix Astragali preparations by solid-phase extraction and high-performance liquid chromatography. J Sep Sci 31: 97–106.
6. Yeohda E, Bedir E, Calis I, Takaishi Y, Ohmoto Y (2005) Effects of triterpene saponins from Astragalus species on in vitro cytokine release. J Ethnopharmacol 96: 71–77.
7. Xu X, Tu P, Chen Y, Zhang T, Wei Y, et al. (2004) Preparative isolation and purification of isoflavans and pteroscarpan glucosides from Astragalus membranaceus Bge. var. mongolicus Bge. Hzuai by high-speed counter-current chromatography. J Chromatogr A 1023: 311–315.
8. Xiao HB, Krucker M, Albert K, Liang XM (2004) Determination and identification of isoflavonoids in Radix astragali by matrix solid-phase dispersion extraction and high-performance liquid chromatography with photodiode array and mass spectrometric detection. J Chromatogr A 1032: 117–124.
9. Zhang D, Wang D, Yu Y (2011) Effects and mechanisms of total flavonoids of radix astragali and calyosin on inhibiting human erythroleukemia cell line K562. Zhongguo Zhong Yao Za Zhi 36: 3502–3505.
10. Yan R, Ko NL, Li SL, Tsai YK, Lin G (2008) Pharmacokinetics and metabolism of ligustilide, a major bioactive component in Rhizoma Chuanxiong, in the rat. Drug Metab Dispos 36: 400–408

11. Lu Q, Qiu TQ, Yang H (2006) Ligustilide inhibits vascular smooth muscle cells proliferation. Eur J Pharmacol 524: 136–140

12. Ji B, Geng P, Lin JG, Shi DZ, Wang YY (2006) [Effects of active components extracted from Qxue BingZhi Recipe on proliferation of vascular smooth muscle cells and expressions of platelet-derived growth factor and its receptor gene]. Zhong Xi Yi Jie He Xue Bao 4: 30–34.

13. Liu EH, Qi LW, Cheng XL, Peng YB, Li P (2010) Simultaneous determination of twelve bioactive constituents in Buyang Huanwu decoction by HPLC-DAD-ELSD and HPLC-TOF/MS. Biomed Chromatogr 24: 125–131.

14. Liu EH, Qi LW, Peng YB, Cheng XL, Wu Q, et al. (2009) Rapid separation and identification of 54 major constituents in Buyang Huanwu decoction by ultrafast HPLC system coupled with DAD-TOF/MS. Biomed Chromatogr 23: 828–842.

15. Zhang J, Yang G, Lin R, Hu Z (2011) Determination of paeoniflorin, calycosin-7-O-beta-D-glucoside, ononin, calycosin and formononetin in rat plasma after oral administration of Buyang Huanwu decoction for their pharmacokinetic study by liquid chromatography-mass spectrometry. Biomed Chromatogr 25: 450–457.

16. Wu YT, Wu MT, Lin CC, Chien CF, Tsai TH, et al. (2011) Pharmacokinetic studies of Chinese medicinal herbs using an automated blood sampling system and liquid chromatography-mass Spectrometry. J Tradition Complement Med 2: 30–40.

17. Reagan-Shaw S, Nihal M, Ahmad N (2008) Dose translation from animal to human studies revisited. FASEB J 22: 659–661.

18. Wu YT, Huang CM, Lin CC, Ho WA, Lin LC, et al. (2010) Oral bioavailability, urinary excretion and organ distribution of melamine in Sprague-Dawley rats by high-performance liquid chromatography with tandem mass spectrometry. J Agric Food Chem 58: 108–113.

19. Hsieh YJ, Liu CS, Tsai TH (2005) Effects of Evodia rutaecarpa and rutaecarpine on the pharmacokinetics of caffeine in rats. Planta Med 71: 640–644.

20. Guidance for Industry. Available: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf. Accessed 2001 May.

21. Zuo Y, Yan M, Fu Y, Liu W, Zhang L, et al. (2009) Determination and quantification of astragalosides in Radix Astragali and its medicinal products using LC-MS. J Sep Sci 32: 517–525.

22. Wen XD, Qi LW, Li B, Li P, Yi L, et al. (2009) Microsomal metabolism of calycosin, formononetin and drug-drug interactions by dynamic microdialysis sampling and HPLC-DAD-MS analysis. J Pharm Biomed Anal 50: 100–105.

23. Tong L, Wan M, Zhou D, Gao J, Zhu Y, et al. (2010) LC-MS/MS determination and pharmacokinetic study of abillorin and paeoniflorin in rat plasma after oral administration of Radix Paeoniae Alba extract and Tang-Ming-Wan. Biomed Chromatogr 24: 1324–1331.

24. Wang D, Song Y, Li SL, Bian YY, Guan J, et al. (2006) Simultaneous analysis of seven astragalosides in Radix Astragali and related preparations by liquid chromatography coupled with electrospray ionization time-of-flight mass spectrometry. J Sep Sci 29: 2012–2022.

25. Lu T, Song J, Huang F, Deng Y, Xie L, et al. (2007) Comparative pharmacokinetics of baicalin after oral administration of pure baicalin, Radix scutellariae extract and Huang-Lian-Jie-Du-Tang to rats. J Ethnopharmacol 110: 412–418.

26. Li P, Zhang Y, Xiao L, Jin X, Yang K (2007) Simultaneous determination of harpagoside and cinnamic acid in rat plasma by high-performance liquid chromatography: application to a pharmacokinetic study. Anal Bioanal Chem 389: 2259–2264.

27. Huang Y, Bai Y, Zhao L, Hu T, Hu B, et al. (2007) Pharmacokinetics and metabolism of nifedrine in rats after a single oral administration. Biopharm Drug Dispos 28: 361–372.

28. Zhu Z, Zhao L, Liu X, Chen J, Zhang H, et al. (2010) Comparative pharmacokinetics of baicalin and wogonoside by liquid chromatography-mass spectrometry after oral administration of Xiaochaihu Tang and Radix scutellariae extract to rats. J Chromatogr B Analyt Technol Biomed Life Sci 878: 2184–2190.

29. Yin OQ, Tomlinson B, Chow AH, Chow MS (2003) A modified two-portion absorption model to describe double-peak absorption profiles of ranitidine. Clin Pharmacokinet 42: 179–192.

30. Mummaneni V, Amador GL, Dressman JB (1995) Gastric pH influences the appearance of double peaks in the plasma concentration-time profiles of cimetidine after oral administration in dogs. Pharm Res 12: 780–786.

31. Mostafavi SA, Foster RT (2003) Influence of cimetidine co-administration on the pharmacokinetics of acetobutol erantioner and its metabolite diacetolol in a rat model: the effect of gastric pH on double-peak phenomena. Int J Pharm 255: 81–86.

32. Tsai PL, Tsai TH (2002) High-performance liquid chromatographic determination of berbine contained in medicinal herbs and a related traditional Chinese medicine. Anal Let 35:2459–2470.

33. Tsai TH, Chang CH, Lin LC (2005) Effects of Euvodia rutacearpa and rutacearpine on the pharmacokinetics of caffeine in rats. Planta Med 71: 640–644.

34. Lin LC, Chen YE, Lee WC, Wu YT, Tsai TH (2008) Pharmacokinetics of gastrodin and its metabolite p-hydroxybenzyl alcohol in rat blood, brain and bile by microdialysis coupled to LC-MS/MS. J Pharm Biomed Anal 48: 909–917.

35. Chen YJ, Huang SM, Liu CY, Yeh PH, Tsai TH (2006) Hepatobiliary excretion and enterohepatic circulation of colchicine in rats. Int J Pharm 350: 230–239.

36. Zhou S, Koh HL, Gao Y, Gong ZY, Lee EJ (2004) Herbal bioactivation: the good, the bad and the ugly. Life Sci 74: 935–968.